Top Markets
Coin of the day
NeuBase Therapeutics, Inc. NeuBase Therapeutics, Inc.

NeuBase Therapeutics, Inc.

NBSE
Hisse Senetlerindeki Sıralama #39174
Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics,... Operating as a pre-clinical biopharmaceutical company, NeuBase Therapeutics, Inc. is dedicated to pioneering therapeutic solutions for rare genetic disorders and various cancers stemming from aberrant genes. At the core of its approach is the proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform. This technology is being utilized to target ailments such as Huntington's disease (HD) and myotonic dystrophy, in addition to a broader spectrum of genetic conditions and applications within oncology. The company's leading therapeutic candidates encompass NT0100, a PATrOL-powered anti-gene therapy for Huntington's disease; NT0200, another PATrOL-enabled anti-gene solution for myotonic dystrophy type 1; and NT0300, a PATrOL-based treatment specifically engineered to address the mutated KRAS gene. NeuBase Therapeutics, Inc. maintains its headquarters in Pittsburgh, Pennsylvania.
Hisse Fiyatı
$0.378
Son senkronizasyon: 2024-05-24
Piyasa Değeri
$618.41K
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret NeuBase Therapeutics, Inc. (NBSE)

Kategori

NeuBase Therapeutics, Inc. (NBSE) için temettü verimi geçmişi
NeuBase Therapeutics, Inc. (hisse sembolü: NBSE) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
NeuBase Therapeutics, Inc. (NBSE) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
Yıl Temettü Verimi Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin temettü verimi (TTM)